<DOC>
	<DOC>NCT00382239</DOC>
	<brief_summary>This study will examine the response of several doses of LY2148568 (exenatide) and assess the effect on glucose control and safety and tolerability in Japanese patients with type 2 diabetes.</brief_summary>
	<brief_title>A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Diagnosed with type 2 diabetes. Have a body weight of &gt;=50 kg. Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. Have participated in this study previously, or any other study using exenatide or other GLP1 analogs. Are treated with any exogenous insulin within 3 months of screening. Are continuously treated with any of the following excluded medications within 3 months of screening (more than 7 days per 1 month): *drugs that directly affect gastrointestinal motility, including Nauzelin® (domperidone), Primperan®/Terperan® (metoclopramide), Ganaton® (itopride), Acenalin® (cisapride), Gasmotin® (mosapride), or Cerekinon® (trimebutine). Have characteristics contraindicating for concomitant medication, according to productspecific label. Have severe allergy or hypersensitivity to any drug.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>LY2148568</keyword>
	<keyword>Lilly</keyword>
	<keyword>Amylin</keyword>
	<keyword>Japan</keyword>
</DOC>